BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 29590221)

  • 1. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
    Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
    PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical safety and efficacy of andexanet alfa in animal models.
    Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
    J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
    Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
    Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.
    Grottke O; Braunschweig T; Rossaint R; Akman N; Leeds JM; Conley PB; Honickel M
    Br J Anaesth; 2019 Aug; 123(2):186-195. PubMed ID: 31202564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
    Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
    J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
    Rogers KC; Finks SW
    Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
    Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
    Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
    Bourdin M; Perrotin D; Mathieu O; Herve T; Depasse F; Lu G; Conley PB; Contant G
    Int J Lab Hematol; 2021 Aug; 43(4):795-801. PubMed ID: 34092030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo reversal of the anticoagulant effects of edoxaban.
    Halim AB; Samama MM; Mendell J
    Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Andexanet alfa (ONDEXXYA
    Yajima T; Higashimori M; Takata C; Sasabe T
    Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet: Effectively Reversing Anticoagulation.
    Lippi G; Sanchis-Gomar F; Favaloro EJ
    Trends Pharmacol Sci; 2016 Jun; 37(6):413-414. PubMed ID: 27048885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-Related Effectiveness of Andexanet Alfa for Reversal of Apixaban Anticoagulation in a Porcine Polytrauma Model.
    Rayatdoost F; Braunschweig T; Schöchl H; Rossaint R; Grottke O
    Thromb Haemost; 2024 Jan; 124(1):20-31. PubMed ID: 37604188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
    Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U
    Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
    Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ;
    Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.